pharm t1 cardiac indications & outcomes

  1. Indications: HTN, angina pectoris & vasospastic (prinzmetal's angina). Supraventricular tachyarrhytmias and rapid ventricular rates in atrial flutter or fibrillation
  2. Desired Outcomes:
    -decrease in BP
    -decrease in freq & severity of anginal attacks
    -decrease in need for nitrate therapy
    -increase in activity tolerance & sense of well-being
    -supression and prevention of tachyarrhythmia
  3. Indications: HTN, angina pectoris, prevention of MI and decreased mortality in pts w/recent MI. Mgmt of stable, symptomatic (class II or III) HF due to ischemic, hypertensive, or cardiomyopathic origin (may be used with ACE inhibitors, diuretics, and/or digoxin.)
    Toprol XL
  4. Unlabeled use: ventricular arrhythmias/tachycardia. Migraine prophylaxis. Tremors. Aggressive behavior. Drug-induced akathasia. Anxiety.
    Toprol XL
  5. Desired Outcomes:
    - Decresed BP
    -Reduction in freq. of anginal attacks
    -increase in activity tolerance
    -Prevention of MI
    Toprol XL
  6. Indications: Life threatening ventricular arrythmias unresponsive to less toxic agents.
  7. Unlabeled Use:
    PO- mgmt of SVTs
    IV-part of ACLS and PALS guidelines for mgmt of vFib/pulseless ventricular tachycardia after CPR and defibrillation have failed. Also for other life-threatening tachyarrhythmias.
  8. Desired Outcomes:
    -cessation of life-threatening ventricular arrhythmias. Adverse effects may take up to 4 months to resolve.
  9. Indications: edema due to CHF, hepatic or renal disease. HTN
  10. Desired Outcomes:
    -decrease in edema
    -decrease in abdominal girth & weight
    -decrease in BP
    -increase in urinary output
  11. Indications: Adjuct to standard measures to improve: Blood pressure, cardiac output, urine output in treatment of shock unresponsive to fluid replacement. Increase renal perfusion (low doses).
  12. Desired Outcomes:
    -Increase in BP
    -Increase in peripheral circulation
    -Increase in urine output
  13. Indications:
    SubQ, IV, Inhaln: Mgmt of reversible airway disease due to asthma or COPD.
    SubQ, IM, IV: mgmt of severe allergic reactions
    IV, Intracardia, Intratracheal, Intraosseous (part of ACLS and PALS guidelines): mgmt of cardiac arrest (unlabeled).
    Inhaln: mgmt of upper airway obstruction and croup (racemic epinephrine).
    Local/spinal: adjunc in the localization/prolongation of anesthesia.
  14. Desired Outcomes:
    -prevention or relief of bronchospasm
    -increase in ease of breathing
    -prevention of bronchospasm or reduction of frequency of acute asthma attacks in pts w/chronic asthma.
    -Prevention of exercise-induced asthma
    -reversal of s/s of anaphylaxis
    -increase in cardiac rate and output, when used in cardaic resuscitation.
    -Increase in BP, when used as vasopressor
    -Localization of local anesthetic
    -Decrease in sinus and nasal congestion
Card Set
pharm t1 cardiac indications & outcomes
pharm t1 cardiac drug indications & outcomes